US-based biopharmaceutical company Microbion has enrolled the first patient in its Phase IIa trial of MBN-101 to treat orthopedic implant-related infections.

MBN-101 is the company’s bismuth-thiol class lead drug candidate, which is being developed to combat against difficult to treat infections.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Its anti-bacterial properties render it effective against a wide range of pathogens, including multiple priority pathogens or superbugs.

MBN-101 has also exhibited its ability to eradicate microbial biofilms.

"When treating difficult infections associated with orthopedic implants, which are increasingly common, physicians urgently need more effective treatments."

The randomised, placebo-controlled, dose ranging Phase IIa trial will enrol patients with implant-related orthopedic infections.

See Also:

The trial is intended to assess the safety and efficacy of MBN-101 in improving patient outcomes who are afflicted with orthopedic implant related infections.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Perelman School of Medicine, University of Pennsylvania orthopaedic surgery associate professor orthopaedic trauma division chief and principal investigator of study Dr Samir Mehta said: "When treating difficult infections associated with orthopedic implants, which are increasingly common, physicians urgently need more effective treatments.

"We are eager to evaluate MBN-101 as a potentially important new treatment for patients with orthopedic infections, as it represents a new therapeutic approach that benefits from recent advances in our understanding of bacteria."

MBN-101 has been awarded the qualified infectious disease product (QIDP) designation by the US Food and Drug Administration (FDA) indicated for post-surgical orthopedic implant infections, and was also granted Fast Track status for this indication by the FDA last year.